Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
atypical antipsychotics
Pharma
FDA signs off on Vanda's Bysanti for schizophrenia and bipolar I
The FDA has approved Vanda's Bysanti as a first-line treatment for schizophrenia or for manic or mixed episodes associated with bipolar I disorder.
Kevin Dunleavy
Feb 23, 2026 11:35am
Otsuka, Lundbeck's Rexulti snubbed by FDA in PTSD
Sep 22, 2025 4:42pm
BMS touts commercial execution, reckons with clinical setbacks
Jul 31, 2025 11:10am
FDA advisors overwhelmingly reject Lundbeck, Otsuka's PTSD drug
Jul 21, 2025 11:34am
FDA questions Rexulti efficacy in PTSD after failed phase 3
Jul 16, 2025 2:38pm
BMS' schizophrenia drug stumbles in blow to blockbuster plan
Apr 23, 2025 10:35am
